이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG (CALM)

2026년 10월 31일 업데이트: China National Center for Cardiovascular Diseases

Cardiac Autonomic Neuromodulation in Myocardial Revascularization (CALM): A Multicenter Randomized Controlled Trial of Partial Cardiac Denervation for the Prevention of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

Postoperative atrial fibrillation (POAF) is the most common arrhythmia following cardiac surgery and is associated with increased risks of mortality, stroke, myocardial infarction, and hospital readmission. The cardiac autonomic nervous system plays an important role in the development of POAF and may represent a potential target for preventive intervention.

The CALM trial is a multicenter, randomized controlled trial designed to evaluate the efficacy and safety of partial cardiac denervation for the prevention of POAF in patients undergoing isolated coronary artery bypass grafting (CABG). A total of approximately 1,470 participants will be randomly assigned in a 1:1 ratio to undergo CABG with partial cardiac denervation or CABG alone. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad.

The trial will evaluate the incidence of POAF within the first 6 postoperative days and the occurrence of long-term adverse clinical events. Participants will undergo scheduled rhythm monitoring and clinical follow-up, and all participants will be followed until the last enrolled participant completes 3 years of follow-up after surgery.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Postoperative atrial fibrillation (POAF) is a common complication after coronary artery bypass grafting (CABG) and is associated with increased risks of stroke, myocardial infarction, prolonged hospitalization, and other adverse outcomes. Autonomic imbalance and excessive activation of the intrinsic cardiac autonomic nervous system are considered important contributors to the development of POAF. Previous studies of pharmacological or biological autonomic modulation have shown variable efficacy, and their effects may be transient.

A previous single-center randomized trial conducted by the investigators showed that partial cardiac denervation, consisting of transection of the ligament of Marshall and resection of the Waterston fat pad, reduced the incidence of POAF after CABG without increasing perioperative complications. The CALM trial is designed to evaluate whether these findings can be reproduced across multiple centers and to investigate the potential long-term clinical and autonomic effects of this intervention.

This is a prospective, multicenter, randomized controlled trial involving approximately 1,470 patients undergoing isolated CABG with or without cardiopulmonary bypass. Participants will be randomly assigned in a 1:1 ratio to partial cardiac denervation in addition to standard CABG or to standard CABG alone. Centralized randomization will be stratified by participating center and baseline CHA2DS2-VASc score. Treatment allocation will be disclosed to the operating surgeon only after induction of anesthesia. Participants, outcome assessors, electrocardiographic reviewers, clinical event adjudicators, and statisticians will remain blinded to treatment allocation.

In the intervention group, the ligament of Marshall, located between the left atrial appendage and the left pulmonary veins, will be transected using electrocautery. The Waterston fat pad, located in the interatrial groove between the right atrium and the right pulmonary veins, will then be completely resected down to the epicardial surface. No additional denervation procedure will be performed in the control group. Other aspects of CABG and perioperative care will follow routine clinical practice at each participating center.

Continuous electrocardiographic monitoring will be performed during the early postoperative period, and scheduled ambulatory electrocardiographic monitoring will be conducted during follow-up. Electrocardiographic recordings will be centrally reviewed by an independent ECG Core Laboratory. Suspected clinical endpoint events will be adjudicated by an independent Clinical Event Adjudication Committee blinded to treatment allocation. Participants will undergo scheduled clinical follow-up for assessment of arrhythmias, cardiac autonomic function, and long-term clinical outcomes. All participants will be followed until the last enrolled participant has completed 3 years of follow-up after surgery.

연구 유형

중재적

등록 (추정된)

1470

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Ziang Yang, M.D.
  • 전화번호: 86+19801109287
  • 이메일: yzang47@163.com

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100000
        • Fuwai Hospital, PUMC & CAMS
        • 연락하다:
        • 수석 연구원:
          • Wei Feng, M.D.
        • 수석 연구원:
          • Zhan Hu, M.D.
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510080
        • Guangdong Provincial People's Hospital
        • 연락하다:
          • Qiang Gao, M.D.
    • Henan
      • Zhenzhou, Henan, 중국, 451464
        • Fuwai Central China Cardiovascular Hospital
        • 연락하다:
          • Junlong Hu, M.D.
    • Hunan
      • Changsha, Hunan, 중국, 410011
        • The Second Xiangya Hospital of Central South University
        • 연락하다:
          • Xiaobo Liao, M.D.
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210006
        • Nanjing First Hospital, Nanjing Medical University
        • 연락하다:
          • Fei Xiang, M.D.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Scheduled to undergo isolated coronary artery bypass grafting, either with or without cardiopulmonary bypass.
  • Able and willing to provide written informed consent.
  • No atrial fibrillation detected on preoperative 24-hour electrocardiographic monitoring.

Exclusion Criteria:

  • Previous cardiac surgery.
  • Emergency surgery.
  • Preoperative critical condition.
  • Left ventricular ejection fraction of 30% or lower.
  • Left atrial diameter greater than 50 mm.
  • Prior history of atrial fibrillation.
  • Use of antiarrhythmic medications other than beta-blockers within 2 weeks before surgery.
  • Planned concomitant cardiac procedures, including but not limited to congenital heart disease surgery or left ventricular reconstruction.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Control group

CABG alone

실험적: Intervention group

Partial cardiac denervation + CABG. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad.

The intervention has been described in previous studies. Briefly, intraoperative partial cardiac denervation is achieved by transection of the left LOM and resection of the right Waterston fat pad using electrocautery.

During the procedure, the pulmonary trunk is first gently retracted to the right to expose the LOM located between the left atrial appendage and the left pulmonary veins. The LOM is then transected using electrocautery. Subsequently, the right atrium is retracted to the left to expose the Waterston fat pad located in the interatrial groove. The Waterston fat pad is completely excised with electrocautery down to the epicardial surface.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of Postoperative Atrial Fibrillation Within 6 Postoperative Days
기간: From admission to the intensive care unit after surgery until postoperative day 6.

The proportion of participants with documented new-onset postoperative atrial fibrillation (POAF). POAF is defined as an episode of atrial fibrillation characterized by irregularly irregular RR intervals and the absence of discernible P waves, lasting more than 30 seconds. Continuous electrocardiographic recordings will be centrally reviewed by the blinded ECG Core Laboratory.

From admission to the intensive care unit after surgery until postoperative day 6.
Time to First Occurrence of the Composite Clinical Outcome
기간: From surgery until 3 years after enrollment of the last participant, with a minimum follow-up of 3 years for each participant.

Time from surgery to the first occurrence of any component of the composite outcome, including all-cause death, stroke, systemic embolism, myocardial infarction, readmission for cardiac reasons, or post-discharge atrial fibrillation. Suspected clinical events will be adjudicated by an independent Clinical Event Adjudication Committee blinded to treatment allocation. Post-discharge atrial fibrillation events will be reviewed by the blinded ECG Core Laboratory.

From surgery until 3 years after enrollment of the last participant, with a minimum follow-up of 3 years for each participant.

2차 결과 측정

결과 측정
측정값 설명
기간
Postoperative Length of Hospital Stay
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)

The number of days from the date of surgery to hospital discharge.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)
Total Hospitalization Costs
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)

Total medical costs incurred during the index hospitalization.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)
Incidence of Perioperative All-Cause Mortality
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)

The proportion of participants who die from any cause during the perioperative hospitalization.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)
Incidence of Perioperative New-Onset Stroke
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)

The proportion of participants who experience a new-onset stroke during the perioperative hospitalization, as adjudicated by the blinded Clinical Event Adjudication Committee according to predefined endpoint criteria.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)
Incidence of Perioperative Myocardial Infarction
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)

The proportion of participants who experience myocardial infarction during the perioperative hospitalization, as adjudicated by the blinded Clinical Event Adjudication Committee according to predefined endpoint criteria.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days)
Postoperative Atrial Fibrillation Burden Within 6 Postoperative Days
기간: From admission to the intensive care unit after surgery until postoperative day 6.

The proportion of analyzable electrocardiographic monitoring time spent in atrial fibrillation during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory.

From admission to the intensive care unit after surgery until postoperative day 6.
Number of Postoperative Atrial Fibrillation Episodes Within 6 Postoperative Days
기간: From admission to the intensive care unit after surgery until postoperative day 6.

The total number of documented postoperative atrial fibrillation episodes per participant during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory.

From admission to the intensive care unit after surgery until postoperative day 6.
Duration of Postoperative Atrial Fibrillation Within 6 Postoperative Days
기간: From admission to the intensive care unit after surgery until postoperative day 6.

The cumulative duration of documented postoperative atrial fibrillation episodes during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory.

From admission to the intensive care unit after surgery until postoperative day 6.
Incidence of Post-Discharge Atrial Fibrillation
기간: From discharge until the end of study follow-up, with a minimum follow-up of 3 years for each participant.

The proportion of participants with atrial fibrillation documented after discharge by scheduled 3-day ambulatory electrocardiographic monitoring or by clinically obtained electrocardiographic recordings. All suspected events will be reviewed by the blinded ECG Core Laboratory.

From discharge until the end of study follow-up, with a minimum follow-up of 3 years for each participant.
Post-Discharge Atrial Fibrillation Burden
기간: At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.

The proportion of analyzable ambulatory electrocardiographic monitoring time spent in atrial fibrillation during each scheduled 3-day monitoring period, as determined by the blinded ECG Core Laboratory.

At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.
Incidence of Non-Atrial Fibrillation Arrhythmias
기간: From surgery until the end of study follow-up, with a minimum follow-up of 3 years for each participant.

The proportion of participants with predefined non-atrial fibrillation arrhythmias, including third-degree atrioventricular block, frequent premature atrial contractions, and frequent premature ventricular contractions, as determined by the blinded ECG Core Laboratory.

From surgery until the end of study follow-up, with a minimum follow-up of 3 years for each participant.
Heart Rate Variability Parameters
기간: During the first 6 postoperative days and at 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.

Cardiac autonomic function will be assessed using time-domain and frequency-domain heart rate variability parameters obtained from electrocardiographic monitoring. Measurements will be centrally analyzed by the blinded ECG Core Laboratory.

During the first 6 postoperative days and at 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.
Health-Related Quality of Life Assessed Using the EuroQol 5-Dimension 5-Level Questionnaire
기간: At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.

Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L). An EQ-5D-5L health utility index will be calculated using the Chinese population value set. The index ranges from -0.391 to 1.000, with higher scores indicating better health status. A score of 1.000 represents full health, 0 represents a health state equivalent to death, and negative values represent health states considered worse than death. Scores will be compared between the two treatment groups at scheduled follow-up assessments.

At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.
Atrial Fibrillation-Related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire
기간: At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.

Atrial fibrillation-related quality of life will be assessed using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT). The AFEQT Overall Summary Score ranges from 0 to 100, with higher scores indicating better atrial fibrillation-related health status and quality of life and lower scores indicating greater impairment. Scores will be compared between the two treatment groups at scheduled follow-up assessments.

At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant.
Incidence of Reoperation for Bleeding
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days).

The proportion of participants who require surgical re-exploration because of postoperative bleeding.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days).
Incidence of Postoperative Blood Transfusion
기간: From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days).

The proportion of participants who receive a blood transfusion after surgery during the index hospitalization.

From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days).
Incidence of Delayed Moderate or Greater Pericardial Effusion
기간: From discharge from the index hospitalization through 30 days after discharge.

The proportion of participants who develop new-onset moderate or greater pericardial effusion within 30 days after discharge from the index hospitalization, as documented by echocardiography.

From discharge from the index hospitalization through 30 days after discharge.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Mario Gaudino, M.D., Weill Medical College of Cornell University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2030년 12월 31일

연구 완료 (추정된)

2030년 12월 31일

연구 등록 날짜

최초 제출

2026년 10월 23일

QC 기준을 충족하는 최초 제출

2026년 10월 31일

처음 게시됨 (실제)

2026년 11월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 31일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCRC2026001
  • 2026-12M-SXZX1-05 (기타 보조금/기금 번호: Chinese Academy of Medical Sciences)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .